CVJ.F AVALA RES
- Market cap
- EUR 830K
- P/E
- 0.1x
- P/B
- 0.05x
- ROE
- 71.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CVJ.F undervalued?
Graham numberThe Graham number of AVALA RES cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AVALA RES fundamental analysis
No fundamental analysis for AVALA RES yet.
AVALA RES stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AVALA RES
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Full company profileAVALA RES financial statements
AVALA RES annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 647K | 4.29M | 6.41M | 13.8M | 15.4M | 8.56M |
| Gross Profit | - | 6.52K | 4.25M | 6.41M | 13.8M | 15.4M | 4.90M |
| Operating Income | - | -17.3M | -23.5M | -29.1M | -36.6M | -27.5M | -11.8M |
| EBITDA | - | - | - | -19.8M | -18.7M | -33.4M | 31.8M |
| Net Income | - | -16.9M | -25.1M | -26.5M | -33.8M | -51.2M | 20.6M |
| EPS | - | -0.12 | -0.09 | -0.07 | -0.09 | -0.11 | 0.01 |
| Balance Sheet | |||||||
| Total Assets | - | 76.4M | 102M | 140M | 129M | 92.8M | 52.0M |
| Total Liabilities | - | 15.3M | 9.92M | 54.8M | 70.2M | 78.9M | 23.0M |
| Shareholders' Equity | - | 61.1M | 91.9M | 84.9M | 59.3M | 13.9M | 29.0M |
| Cash & Short-term Investments | - | 1.55M | 3.11M | 1.91M | 765K | 1.64M | 490K |
| Cash Flow | |||||||
| Capital Expenditure | 0.00 | 34.4M | 16.3M | 45.2M | 3.10M | 2.51M | 406K |
| Free Cash Flow | - | -52.0M | -37.1M | -65.6M | -25.9M | -17.7M | -1.74M |
| Ratios | |||||||
| ROE | - | -27.7% | -27.3% | -31.2% | -57.0% | -368.1% | 71.1% |
| ROA | - | -22.2% | -24.7% | -19.0% | -26.1% | -55.2% | 39.7% |
| Net Profit Margin | - | -2,616.9% | -584.7% | -412.9% | -245.3% | -333.3% | 240.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AVALA RES dividends
AVALA RES has not paid dividends in the last 7 fiscal years.
Who owns AVALA RES
- Insiders 21.98%
- Institutions 3.60%
- Public & others 74.43%
- Shares outstanding 1.66B
- Free float 1.31B
AVALA RES company profile
- Company name
- AVALA RES
- Ticker
- CVJ.F
- ISIN
- AU000000CAN2
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- 23 Greentek Court, Mildura, VIC, Australia, 3501
- Phone
- 61 3 9095 7088
- Website
- canngrouplimited.com
About AVALA RES
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
AVALA RES management
2- Mr. Michael Joseph RyanInterim Executive Chairman
- Mr. Steven Notaro BA, J.D.VP Compliance & Company Secretary